Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on the eye doctor: can software match expert glaucoma grading?

NCT ID NCT07820709

Diagnosis Sponsor: University of Salerno Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers at the University of Salerno are testing whether an artificial intelligence system can grade glaucoma severity from standard visual field tests as reliably as an expert ophthalmologist. The study follows about 50 adults with glaucoma or suspected glaucoma who have visual field exams at the start and roughly one year later. Both the AI and the eye doctor stage each test using the Brusini Glaucoma Staging System 2, a scale from Stage 0 to Stage 5, and the researchers compare how closely their ratings agree. The AI only reads the tests and does not influence patient treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an artificial intelligence system that stages glaucoma severity from visual field tests
What this could lead to
If the AI grades glaucoma severity as reliably as an eye specialist, it could help clinics sort patients faster and track their vision loss more consistently.
What could go wrong
This is a small study of 50 people at one center, so the AI may not match expert judgment in other clinics or with different visual field machines. The AI only reads test results and does not change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Apr 2011

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with glaucoma or suspected glaucoma attending the Ophthalmology Unit of University of Salerno for routine glaucoma follow-up. Eligible participants underwent standard automated visual field testing at baseline and approximately 1-year follow-up. Visual fields were independently staged by an artificial intelligence system and an expert ophthalmologist using the Brusini Glaucoma Staging System 2 (GSS2).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years of age). * Diagnosis of glaucoma or suspected glaucoma undergoing routine clinical follow-up. * Availability of reliable standard automated visual field (VF) examinations at baseline and approximately 1-year follow-up. * Visual field tests suitable for staging using the Brusini Glaucoma Staging System 2 (GSS2). * Availability of all clinical data required for study analysis. Exclusion Criteria: * Unreliable visual field examinations (e.g., excessive fixation losses, false-positive or false-negative responses according to institutional reliability criteria). * Visual field defects attributable to ocular or neurological diseases other than glaucoma. * Missing baseline or follow-up visual field examinations. * Incomplete clinical data preventing GSS2 staging or statistical analysis. * Previous ocular conditions or interventions that could significantly affect visual field interpretation, if judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma and ocular hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma and ocular hypertension

Contacts and locations

Locations

  • University of Salerno

    Salerno, 84084, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.